Cybin Inc.
CYBN.NE
Get informed when a big investor buys or sells
+ FollowMarket Cap$731.41M
Close$
$4.52
69.7% downside
Current Fair Value
69.7% downsideOvervalued by 69.7% based on the discounted cash flow analysis.
Share Statistics
| Market cap | $731.41 Million |
|---|---|
| Enterprise Value | $565.32 Million |
| Dividend Yield | $- (-) |
| Earnings per Share | $-4.22 |
| Beta | -0.95 |
| Outstanding Shares | 52,318,151 |
Return
| Return on Equity | -70.01% |
|---|---|
| Return on Assets | -65.27% |
| Return on Invested Capital | -68.27% |
Valuation & Multiples
| P/E Ratio | -2.84 |
|---|---|
| PEG | -3.18 |
| Price to Sales | - |
| Price to Book Ratio | 3.73 |
| Enterprise Value to Revenue | - |
| Enterprise Value to EBIT | -3.43 |
| Enterprise Value to Net Income | -4 |
| Total Debt to Enterprise | 0 |
| Debt to Equity | 0 |
Revenue Sources
No data
Insider Trades
Last Earnings Call
Report Date
August 14, 2026
EPS Estimate
$-1.20
Average shareholder expectationRevenue Estimate
-
Average shareholder expectationNext Earnings Call
Expected Date
November 16, 2026
EPS Estimate
$-1.00
Average shareholder expectationRevenue Estimate
-
Average shareholder expectationInstitutional Sentiment (Put/Call)
No data available for the latest quarter.
Institutional Ownership
No data available for the latest quarter.
ESG Score
No data
About Cybin Inc
100 employees
CEO: Michael I. Halstead Cybin, Inc. operates as a clinical-stage biopharmaceutical company on a mission to create safe and effective psychedelic-based therapeutics to address the large unmet need for new and innovative treatment options for people who suffer fr...